These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 3878765)
21. C3 activation products, C3 containing immune complexes, the terminal complement complex and native C9 in patients with rheumatoid arthritis. Olmez U; Garred P; Mollnes TE; Harboe M; Berntzen HB; Munthe E Scand J Rheumatol; 1991; 20(3):183-9. PubMed ID: 2068540 [TBL] [Abstract][Full Text] [Related]
22. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b. Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466 [TBL] [Abstract][Full Text] [Related]
23. Quantitation of activation of the human terminal complement pathway by ELISA. Sanders ME; Schmetz MA; Hammer CH; Frank MM; Joiner KA J Immunol Methods; 1985 Dec; 85(2):245-56. PubMed ID: 2416846 [TBL] [Abstract][Full Text] [Related]
24. Demonstration of C3d and the terminal complement complex on thymic large granular lymphocytes and common thymocytes after incubation with naturally thymocytotoxic serum. Sandberg G; Stenvinkel C; Mollnes TE Int Arch Allergy Appl Immunol; 1988; 87(3):239-46. PubMed ID: 3264545 [TBL] [Abstract][Full Text] [Related]
25. Complexes between C1q and C3 or C4: novel and specific markers for classical complement pathway activation. Wouters D; Wiessenberg HD; Hart M; Bruins P; Voskuyl A; Daha MR; Hack CE J Immunol Methods; 2005 Mar; 298(1-2):35-45. PubMed ID: 15847795 [TBL] [Abstract][Full Text] [Related]
26. A novel ELISA for the assessment of classical pathway of complement activation in vivo by measurement of C4-C3 complexes. Zwirner J; Dobos G; Götze O J Immunol Methods; 1995 Oct; 186(1):55-63. PubMed ID: 7561148 [TBL] [Abstract][Full Text] [Related]
27. Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9. Milis L; Morris CA; Sheehan MC; Charlesworth JA; Pussell BA Clin Exp Immunol; 1993 Apr; 92(1):114-9. PubMed ID: 7682159 [TBL] [Abstract][Full Text] [Related]
28. Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway. Makinde VA; Senaldi G; Jawad AS; Berry H; Vergani D Ann Rheum Dis; 1989 Apr; 48(4):302-6. PubMed ID: 2785367 [TBL] [Abstract][Full Text] [Related]
29. Increased amounts of C4-containing immune complexes and inefficient activation of C3 and the terminal complement pathway in a patient with homozygous C2 deficiency and systemic lupus erythematosus. Garred P; Mollnes TE; Thorsteinsson L; Erlendsson K; Steinsson K Scand J Immunol; 1990 Jan; 31(1):59-64. PubMed ID: 2300790 [TBL] [Abstract][Full Text] [Related]
30. Sensitive ELISA for quantitating the terminal membrane C5b-9 and fluid-phase SC5b-9 complex of human complement. Hugo F; Krämer S; Bhakdi S J Immunol Methods; 1987 May; 99(2):243-51. PubMed ID: 3584995 [TBL] [Abstract][Full Text] [Related]
32. Activation of the complement system by antibody-antigen complexes: the classical pathway. Porter RR; Reid KB Adv Protein Chem; 1979; 33():1-71. PubMed ID: 396780 [No Abstract] [Full Text] [Related]
33. Circulating complement breakdown products in patients with rheumatoid arthritis. Correlation between plasma C3d, circulating immune complexes, and clinical activity. Nydegger UE; Zubler RH; Gabay R; Joliat G; Karagevrekis CH; Lambert PH; Miescher PA J Clin Invest; 1977 May; 59(5):862-8. PubMed ID: 853126 [TBL] [Abstract][Full Text] [Related]
34. In vitro fixation of C3d and C5b-9 on platelets by human platelet reactive antibodies. Kiefel V; Salama A; Mueller-Eckhardt C Blut; 1989 Jan; 58(1):33-7. PubMed ID: 2783867 [TBL] [Abstract][Full Text] [Related]
35. Complement levels and C3 breakdown products in open-heart surgery: association of C3 conversion with the postpericardiotomy syndrome. Meri S; Verkkala K; Miettinen A; Valtonen V; Linder E Clin Exp Immunol; 1985 Jun; 60(3):597-604. PubMed ID: 3874733 [TBL] [Abstract][Full Text] [Related]
36. Detection and quantification of the terminal C5b-9 complex of human complement by a sensitive enzyme-linked immunosorbent assay. Mollnes TE; Lea T; Harboe M Scand J Immunol; 1984 Aug; 20(2):157-66. PubMed ID: 6474098 [TBL] [Abstract][Full Text] [Related]
37. The terminal complement complex, C5b-9, a marker of disease activity in patients with systemic lupus erythematosus. Gawryl MS; Chudwin DS; Langlois PF; Lint TF Arthritis Rheum; 1988 Feb; 31(2):188-95. PubMed ID: 3348822 [TBL] [Abstract][Full Text] [Related]
39. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage. Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297 [TBL] [Abstract][Full Text] [Related]
40. Activation of complement in IgA nephropathy. Wyatt RJ; Julian BA Am J Kidney Dis; 1988 Nov; 12(5):437-42. PubMed ID: 3055972 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]